40608-06-8

Basic information

• Product Name: Bis(4-oxopentanoic acid)anhydride
• Synonyms: Bis(4-oxopentanoic acid)anhydride;Di(4-oxopentanoic)anhydride;Dilevulinic anhydride;Levulinic anhydride
• CAS NO: 40608-06-8
• Molecular Formula: C₁₀H₁₄O₅
• Molecular Weight: 214.21516
• Mol File: 40608-06-8.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 70-75 °C
• Appearance: /
• Density: 1.136±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Bis(4-oxopentanoic acid)anhydride(CAS DataBase Reference)
• NIST Chemistry Reference: Bis(4-oxopentanoic acid)anhydride(40608-06-8)
• EPA Substance Registry System: Bis(4-oxopentanoic acid)anhydride(40608-06-8)

Safety Data

• Hazardous Substances Data: 40608-06-8(Hazardous Substances Data)

Upstream product

• 123-76-2 levulinic acid 

Downstream Products

• 96026-71-0 4-Oxo-pentanoic acid (2R,3S,4R,5R)-5-(6-benzoylamino-purin-9-yl)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-hydroxy-tetrahydro-furan-3-yl ester 
• 133510-53-9 5'-O-levulinoyl-3'-O-methylthiomethyl-N³-benzoyl-thymidine 
• 133527-00-1 5'-O-levulinoyl-3'-O-(4-pentenyloxymethyl)-N³-benzoyl-thymidine 
• 138935-14-5 p-Methoxyphenyl O-(2,4-di-O-benzyl-3-O-levulinoyl-6-O-pivaloyl-β-D-galactopyranosyl)-(1->4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 
• 76991-48-5 2'-O-levulinyl-3'-O-methyl-6-N-p-anisoyladenosine 
• 82755-02-0 allyl 3-O-benzyl-4-O-levulinoyl-6-O-palmitoyl-2-deoxy-2-(palmitoylamino)-β-D-glucopyranoside 
• 110236-63-0 4-Oxo-pentanoic acid (2S,3R,4S,5R,6S)-5-acetoxy-4-benzyloxy-6-((2R,3S,4R,5R,6S)-4-benzyloxy-5-benzyloxycarbonylamino-2-benzyloxymethyl-6-methoxy-tetrahydro-pyran-3-yloxy)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-tetrahydro-pyran-3-yl ester 
• 135944-14-8 4-Oxo-pentanoic acid (2R,3R,4R,5R)-5-[4-(9H-fluoren-9-ylmethoxycarbonylamino)-2-oxo-2H-pyrimidin-1-yl]-2-[(4-methoxy-phenyl)-diphenyl-methoxymethyl]-4-(4-oxo-pentanoyloxy)-tetrahydro-furan-3-yl ester 
• 135944-29-5 4-Oxo-pentanoic acid (2R,3R,4R,5R)-5-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-6-oxo-1,6-dihydro-purin-9-yl]-2-[(4-methoxy-phenyl)-diphenyl-methoxymethyl]-4-(4-oxo-pentanoyloxy)-tetrahydro-furan-3-yl ester 
• 91592-83-5 C₅₁H₄₈ClN₈O₁₄P 
• 92982-63-3 1-O-allyl-2-O-benzyl-3-O-(4-oxovaleryl)-sn-glycerol 
• 90678-77-6 4-Oxo-pentanoic acid (2R,3S,5R)-5-(6-benzoylamino-2-isobutyrylamino-purin-9-yl)-2-(tert-butyl-diphenyl-silanyloxymethyl)-tetrahydro-furan-3-yl ester 
• 121637-79-4 C₅₈H₅₆ClN₈O₁₆PS 
• 143826-32-8 N-benzyloxycarbonyl-3-aminopropyl 2,4-di-O-benzyl-6-O-tert-butyldimethylsilyl-3-O-levulinoyl-β-D-galactopyranoside 

Relevant articles and documents

PRODRUGS OF TRICIRIBINE AND TRICIRIBINE PHOSPHATE

A prodrug composition is provided which includes a pharmaceutical species and an amino acid having a covalent bond to the pharmaceutical species. Particular pharmaceutical species are 6- amino-4-methyl-8-(beta.-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine, also known as TCN and by the trade name tricirinine; as well as the 5 'phosphate of tricirine. TCN and TCNP prodrugs of the present invention have increased bioavailability compared to the parent TCN and TCNP. The inventive prodrug is transported from the gastrointestinal lumen by a specific transporter and is enzymatically cleaved to yield TCN or TCNP, such that TCN or TCNP is delivered to the individual.